New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
10:50 EDTPDIIPDI, Inc. subsidiary presents new data at AACE on ThyraMIR, ThyGenX
Subscribe for More Information
May 12, 2015
16:08 EDTPDIIPDI, Inc. raises FY15 revenue to $136M-$140M from $131M-$140M
Subscribe for More Information
16:06 EDTPDIIPDI, Inc. reports Q1 EPS (26c), two estimates (48c)
Reports Q1 revenue $38.32, two estimates $33.20M. "As we move into the second quarter, our commercialization RFP pipeline is increasingly strong," said the company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use